News

  • Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study

    Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that the Phase 1 study of GEM103, the Company’s investigational treatment for dry AMD, met all its endpoints.

  • Gemini Therapeutics to Participate in Upcoming Investor Conferences

    Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenberg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November.

  • Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration

    CAMBRIDGE, Mass. and SAN FRANCISCO – October 15, 2020 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), and FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement. Upon closing of the transaction, the company will be renamed “Gemini Therapeutics, Inc.” (Combined Company) and will be led by Jason Meyenburg, Chief Executive Officer of Gemini. The Combined Company’s common stock is expected to be listed on Nasdaq.

  • Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration

    CAMBRIDGE, Mass. —(BUSINESS WIRE)— Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced the initiation of enrollment in its Phase 2a “ReGAtta” study.

  • Gemini Therapeutics Appoints Dr. Tuyen Ong as Independent Director

    Ophthalmology innovator brings more than 20 years of clinical and drug development experience to the Board of Directors. CAMBRIDGE, Mass. —(BUSINESS WIRE)— Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that Dr. Tuyen Ong has been appointed to serve

  • Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical Officer

    CAMBRIDGE, Mass. – May 7, 2020 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that Marc E. Uknis MD, FACS has been appointed to serve as Chief Medical Officer, effective today. Dr. Uknis brings more than 35 years of

  • Gemini Therapeutics Appoints David Lubner as Independent Director

    CAMBRIDGE, Mass. – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that David Lubner has been appointed to serve as an independent member of its Board of Directors. “David is an accomplished finance executive, with more than 20 years of

  • Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for Age-related Macular Degeneration

    CAMBRIDGE, Mass.—(BUSINESS WIRE)—Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD. Under the terms of the agreement, SERI and Gemini will explore

  • Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration

    Study is enrolling patients with high-risk genetic variants for dry AMD, a common cause of blindness. Potential to initiate a Phase 2 study supported by the CLARITY natural history study data. Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry age-related macular degeneration (AMD) and linked ocular disorders, today announced it

  • Gemini Therapeutics Announces Leadership Appointment

    Jason Meyenburg Joins Gemini Therapeutics as CEO Cambridge, Mass., September 13, 2019 – Gemini Therapeutics, a precision medicine company developing innovative treatments for age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Jason Meyenburg, MBA, as Chief Executive Officer (CEO). Mr. Meyenburg will also join the company’s Board of Directors. “We are thrilled